Depression Project

AddThis

Print

email this

Major depressive disorder (MDD) is a common, life-threatening illness and a significant cause of disease burden worldwide Monoamine neurotransmitter reuptake inhibitors, both selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), are major classes of antidepressant drugs However, even though SSRIs and SNRIs are effective drugs, many patients fail to respond adequately to monoamine reuptake inhibitor therapy We propose to take advantage of a large, ongoing pharmacogenomic study of SSRI and SNRI efficacy and side effects to test the hypothesis that pharmacometabolomic analysis might help make it possible to identify biomarkers for SSRI and/or SNRI drug response phenotypes We have already obtained preliminary data that support the use of metabolomics to develop novel mechanistic hypotheses for SSRI response, to guide pharmacogenomic studies of variation in SSRI/SNRI response phenotypes and to guide studies performed with model systems The clinical samples for these studies, like those for many of the other “Bridging Projects” in this proposal, are available as a result of a collaboration with the NIH Pharmacogenomics Research Network (PGRN).


Depression Team

 

 

Richard Weinshilboum  David Mrazek  Karen Snyder  Maureen Drews  
Richard WenshilboumDavid MrazekKaren SnyderMaureen Drews